ISPOR Europe - The Professional Society for Health Economics and Outcomes Research
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to ISPOR Europe - The Professional Society for Health Economics and Outcomes Research — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
ISPOR Europe 2026 — Event Research & Buyer/Attendee Intelligence
ISPOR Europe 2026 is the Society’s European flagship conference focused on Health Economics and Outcomes Research (HEOR), convening healthcare leaders and decision-makers to discuss and disseminate the latest trends in healthcare access through science and policy.
1) Event basics (verified)
- Official event title: ISPOR Europe 2026
- Dates: 8–11 November 2026
- Venue city/country: Vienna, Austria
- Event theme (from official text): Shaping the Future of Access Through Science and Policy
- Core conference area: HEOR (Health Economics and Outcomes Research)
2) Who attends (BUYERS / ATTENDEES)
ISPOR Europe 2026 is explicitly positioned as a meeting of healthcare ecosystem stakeholders. Based on the event’s official “Why Attend” section, the attendee mix spans multiple stakeholder categories—meaning it is both research- and decision-oriented. For buyer identification, we focus on the roles that influence evidence generation, evidence standards, health technology assessment (HTA) workflows, reimbursement decisions, pricing/access strategies, and policy-level adoption of outcomes research.
Main attendee groups (as stated by the event):
- Researchers (academic, clinical, and methodological experts working on outcomes evidence)
- Regulators (stakeholders involved in evidence expectations and regulatory submissions)
- Payers (organizations that evaluate value and outcomes to inform coverage/reimbursement)
- Policymakers (governmental or quasi-government bodies shaping access frameworks)
- Life sciences innovators (pharma/biotech/medical technology companies and their evidence teams)
- Providers (healthcare delivery organizations and decision-makers operating within healthcare systems)
- Patient organizations (representing patient perspectives and engagement in outcomes research)
Buyer lens (who is most likely to purchase services or solutions): in an HEOR conference like this, “buyers” are typically found among organizations building or commissioning evidence, running HTA/value assessment, coordinating real-world evidence strategies, managing payer/policy submissions, and supporting outcomes measurement approaches.
High-probability buyer personas (job-title style):
- HEOR / Value & Access leadership (directors, VPs, heads of evidence)
- Health Technology Assessment (HTA) leaders and evidence submission managers
- Real-world evidence (RWE) and outcomes research managers
- Pricing & reimbursement decision-support roles
- Policy and payer engagement leaders
- Research and methodology leads (when purchasing platforms, data, or consulting)
- Provider-side health outcomes and analytics leaders
- Regulatory-facing evidence strategy leaders (where applicable)
- Patient engagement/program managers (where engagement services/tools are involved)
3) Where the show is happening + attendee geographic origin
Location: Vienna, Austria. ISPOR Europe 2026 is a European conference; however, ISPOR emphasizes its international reach.
Attendee geographic origin (from official “Why Attend”): the conference attracts attendees from more than 100 countries. This implies the audience is globally international, even while the meeting is geographically hosted in Europe.
Practical geographic expectations for targeting: expect a strong concentration from European markets (given the event’s regional identity), complemented by global participation from organizations with cross-border evidence and access strategies.
- Primary expectation: Europe-wide (multi-country) payer/policy/HTA and life sciences evidence professionals
- Secondary expectation: global participation from international pharma/biotech and evidence/data providers
- Likely mix: research institutions and multinational stakeholders using shared HEOR methodologies and evidence standards
4) Audience reach (Local / National / Global)
This is global reach in practice, even though it is hosted in a specific European city. The official conference page states:
- Countries represented: 100+ countries
- Attendee size: 6,000+ attendees
The audience therefore functions as a global professional marketplace for HEOR, where evidence standards, access strategies, and policy trends are discussed across countries.
5) Sample buyer company names (BUYERS ONLY) + websites
We can provide an attendee/buyer list only when we align it to what your client sells. ISPOR Europe includes many stakeholder categories; some exhibitors/partners provide data, analytics, consulting, HTA support, RWE generation, and patient engagement solutions, while others focus on scientific exchange. Because we do not have your client product details yet, we should not finalize “best fit buyer” targets without that input.
Important note for accuracy: the official page provides attendee category counts but does not list exhibitor/buyer company names in the text you shared. If we receive your client website/product description, we will map buyers precisely to your offering.
What we can do immediately (template readiness): once we receive your client website, we will generate a targeted buyer table with: Priority, Company, Website, Best Title to Target, and Why This is a Good Buyer Fit.
6) Job profiles, industries & event type
Event type: Professional society conference in the HEOR domain; a multi-stakeholder meeting spanning research, outcomes methods, healthcare policy, and evidence used for access decisions.
Industries involved (inferred from official attendee categories):
- Healthcare & life sciences (life sciences innovators)
- Pharmaceuticals & biotechnology evidence functions
- Medical devices (commonly represented in outcomes/HTA/evidence discussions—confirm once we map your client)
- Payers / health insurers / reimbursement stakeholders
- Healthcare providers
- Health policy institutions
- Regulatory bodies
- Patient organizations (patient-centered outcomes influence)
- Research organizations and academic groups
Job profiles to target (job-title style):
- Director / Head of Health Economics & Outcomes Research
- Director / VP of Value & Access (HEOR-driven evidence)
- HTA Evidence Manager / Head of HTA
- Real-World Evidence (RWE) Manager / Director
- Outcomes Research Scientist / Principal Scientist
- Health Policy Advisor / Policy & Outcomes Lead
- Medical Affairs Evidence Strategy roles (when relevant)
- Payer Engagement Manager / Reimbursement Strategy Manager
- Patient Engagement & Outcomes Program Manager
- Provider-side Population Health / Outcomes & Analytics leadership
- Research Methods & Epidemiology leadership (for methodology/data providers)
Event-specific topic coverage (from official session framing):
- Over 140+ sessions
- Breakout sessions and workshops across 12 taxonomy areas
- 3 plenary sessions and ISPOR Forums
7) Estimated attendance (expected total footfall)
The official conference page states that ISPOR Europe 2026 expects: 6,000+ attendees.
For buyer engagement planning, this matters because it supports a dense professional audience. However, HEOR conferences include a mix of scientific presentations, poster sessions, policy/HTA discussions, and networking formats—so buyer density depends on the specific role you target (evidence leaders, HTA teams, payers, and policy stakeholders are typically the most “commercially actionable”).
8) Key focus areas & buyer engagement
ISPOR Europe is explicitly designed around how evidence supports access and decision-making. From the official page, the conference’s “Why Attend” positioning emphasizes:
- Global participation (100+ countries)
- Healthcare ecosystem networking across researchers, regulators, payers, policymakers, life sciences innovators, providers, and patient organizations
- High session volume (140+ sessions and multiple plenaries)
- Multi-area coverage (12 taxonomy areas plus issue panels and workshops)
What engagement should look like for “buyers”:
Buyer engagement is strongest when the message aligns to the way HEOR teams work: producing evidence, aligning with HTA/value assessment frameworks, supporting payer/policy decision processes, and demonstrating outcomes with credible methods and data.
Key focus areas we would map to buyer needs:
- Value assessment and evidence generation
- Health Technology Assessment (HTA) alignment
- Outcomes research methodology and best practices
- Real-world evidence and evidence quality
- Patient-centered outcomes and stakeholder engagement
- Policy and access considerations (science + policy intersection)
- Evolving HEOR trends discussed through plenaries and forums
Buyer engagement angles (examples of positioning):
- “We help HEOR teams strengthen evidence packages for access decisions.”
- “We support HTA and value assessment workflows with measurable, method-aligned outputs.”
- “We enable more reliable real-world evidence generation or evidence synthesis.”
- “We support patient engagement practices in outcomes research.”
- “We connect payer/policy evidence needs with research execution.”
9) Client-product fit check (required input) — best buyers based on your client requirement
To recommend the best buyer organizations for ISPOR Europe 2026 based on your client’s requirements, we need your client product details.
Please provide:
- Client website URL
- 1–2 sentence summary of what the client sells (e.g., “RWE platform,” “HEOR consulting,” “patient engagement services,” “HTA submissions support,” “outcomes data/analytics,” etc.)
- Whether the client sells to payers, life sciences, providers, or research organizations (if known)
- Any priority geographies (e.g., EU markets, UK, DACH, Nordics, Southern Europe)
How we will use that input: we will align your offering to ISPOR buyer roles and produce a final prioritized buyer list (including the exact table columns you requested: Priority, Company, Website, Best Title to Target, Why This is a Good Buyer Fit). If the client website is not provided, we will keep the “buyers-only company names” section in a template-ready state to avoid guessing.
10) Suggested industries (aligned to an Apollo-like industry taxonomy)
ISPOR Europe spans HEOR and healthcare evidence, so the most relevant industry categories typically map to the following taxonomy options (chosen for close alignment to how buyers operate):
- Hospital & Health Care (providers, outcomes/patient care analytics, healthcare delivery organizations)
- Hospitality (not a primary HEOR buyer fit; only relevant if the client sells event services—usually not the case)
- Medical Devices (if applicable to the client—often present in outcomes/HTA discussions)
- Pharmaceuticals (life sciences evidence functions)
- Medical Practice (some provider organizations and clinical evidence teams)
- Research (methodology, evidence generation, academic and research groups)
- Market Research (patient insights, outcomes surveys, evidence studies when relevant)
- Professional Training & Coaching (only if the client provides HEOR training/education programs)
- Information Technology & Services (if the client is a HEOR software platform, analytics, or data infrastructure)
- Computer Software (if the client’s product is software used for outcomes/RWE/HEOR workflows)
- Health, Wellness & Fitness (generally lower priority unless the client focuses on outcomes in wellness settings)
- Renewables & Environment (not applicable to this event’s primary domain)
Next step: once your client website is shared, we will narrow this to a short, high-precision set that matches how your buyers actually get evaluated and purchased.
11) Sample buyer table (placeholder-ready — requires client website to finalize)
Below is the exact table structure we will deliver with 15–20 buyer samples using your client requirements. Because we do not yet have the client website/product positioning, this section remains as a placeholder so that we can populate accurate companies and job titles after you share the website.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | [To be filled after client website review] | [HEOR/Value & Access/HTA or relevant role] | [Mapped to client’s HEOR/HTA/RWE/patient outcomes needs] | |
| 2 | [To be filled after client website review] | [HEOR/Outcomes research leadership] | [Mapped to evidence-generation workflow] | |
| 3 | [To be filled after client website review] | [RWE/Real-world evidence roles] | [Mapped to RWE execution or evidence synthesis] | |
| 4 | [To be filled after client website review] | [HTA Evidence / Value Assessment] | [Mapped to HTA/value frameworks] | |
| 5 | [To be filled after client website review] | [Payer engagement / reimbursement strategy] | [Mapped to coverage/reimbursement evidence needs] | |
| 6 | [To be filled after client website review] | [Policy and outcomes roles] | [Mapped to access frameworks and policy translation] | |
| 7 | [To be filled after client website review] | [Patient engagement/outcomes program management] | [Mapped to patient-centered evidence and engagement] | |
| 8 | [To be filled after client website review] | [Provider outcomes/analytics leadership] | [Mapped to outcomes reporting and evidence-informed care] | |
| 9 | [To be filled after client website review] | [Evidence strategy / submissions leadership] | [Mapped to evidence package development] | |
| 10 | [To be filled after client website review] | [Research methods / epidemiology leadership] | [Mapped to credible methodology and study execution] | |
| 11 | [To be filled after client website review] | [Value & Access director] | [Mapped to access decision support workflows] | |
| 12 | [To be filled after client website review] | [RWE platform/program owner] | [Mapped to RWE tooling and data strategy] | |
| 13 | [To be filled after client website review] | [Outcomes research procurement lead / evidence program buyer] | [Mapped to sourcing of HEOR and outcomes support] | |
| 14 | [To be filled after client website review] | [HTA partner/vendor management role] | [Mapped to evaluation and partner selection cycles] | |
| 15 | [To be filled after client website review] | [HEOR analytics / decision support] | [Mapped to outcomes reporting and analytics needs] | |
| 16 | [To be filled after client website review] | [Public sector/policy outcomes roles] | [Mapped to policy and access science translation] | |
| 17 | [To be filled after client website review] | [Clinical evidence / outcomes strategy] | [Mapped to bridging clinical outcomes to value decisions] | |
| 18 | [To be filled after client website review] | [Patient organization engagement leadership] | [Mapped to patient-centered outcomes priorities] | |
| 19 | [To be filled after client website review] | [Provider population health / outcomes leadership] | [Mapped to measurement, reporting, and outcomes improvement] | |
| 20 | [To be filled after client website review] | [HEOR methodology / training lead] | [Mapped to methodology standardization and capacity building] |
12) What we need from you to finalize the “best buyers” list
Please share the client website URL so we can review it and return a true best-fit buyer shortlist for ISPOR Europe 2026. Once we have that, we will:
- Select the most relevant buyer organizations across payers, life sciences evidence teams, providers, and policy/HTA stakeholders based on your offering
- Provide 15–20 buyer samples with websites, precise job titles, and clear fit reasoning
- Map the final buyer industries using the industry taxonomy categories most appropriate to your product
Ready when you are: send the client website and a 1–2 line description of what the client sells, and we will produce the fully populated 15–20 buyer table and the final prioritized targeting recommendations for ISPOR Europe 2026 (8–11 November 2026, Vienna, Austria).
Data sheet
| Event Name | ISPOR Europe 2026 |
| Event Date | 8–11 November 2026 |
| Event Status | Upcoming |
| Venue | Not publicly confirmed in the provided official text |
| City | Vienna |
| State / Region | Vienna (federal state) |
| Country | Austria |
| Organizer | ISPOR (International Society for Pharmacoeconomics and Outcomes Research) |
| Official Event Website | ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2026 |
| Event Type | Professional association conference / scientific congress / healthcare outcomes event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Business Services; Education & Training |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | 6,000+ attendees (officially stated on the event page) |
| Attendance Data Reliability | High for projected attendance; official organizer figure published on the event page |
| Main Purpose of Event | To convene healthcare leaders for discussion and dissemination of the latest trends in health economics and outcomes research (HEOR), access, policy, evidence generation, and value assessment |
ISPOR Europe 2026 is the European flagship conference of the International Society for Pharmacoeconomics and Outcomes Research, focused on health economics and outcomes research (HEOR), health technology assessment, value assessment, real-world evidence, and healthcare access. The official event page describes it as a leading European conference for HEOR, with a program built around scientific exchange, policy discussion, and evidence-driven healthcare decision-making.
The event is highly relevant for pharmaceutical companies, biotech firms, payers, providers, regulators, consultancies, and researchers seeking to influence or understand access and reimbursement dynamics. It is a strong environment for B2B networking, partnering, market access intelligence, evidence generation services, consulting, analytics, and healthcare technology solutions aligned to payer and policy stakeholders.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Payers and reimbursement teams | Health insurers, HTA bodies, national reimbursement agencies | Decision-making and evidence review | Core audience for value dossiers, HEOR tools, RWE, and market access solutions |
| Pharma market access leaders | Pharmaceutical manufacturers | Budget ownership and vendor selection influence | High relevance for evidence generation, payer research, and health economics services |
| HEOR / RWE teams | Pharma, biotech, medtech, consulting firms | Technical evaluators and project owners | Primary users of analytics, evidence synthesis, and data platforms |
| Regulators and policymakers | Government health agencies, ministries, HTA organizations | Policy influence and standards-setting | Important for policy intelligence, advisory services, and evidence-based engagement |
| Healthcare providers and systems | Hospitals, integrated delivery systems, provider networks | Adoption and utilization decisions | Relevant for outcomes, pathways, digital health, and value improvement offerings |
| Patient organizations | Disease advocacy groups, patient associations | Influence, insights, and advocacy | Useful for patient-centric research, engagement tools, and communications services |
| CROs / consultancies | Research consultancies, HEOR vendors, strategy firms | Service buyers and influencers | Strong prospects for data, software, research, and outsourced analysis |
| Academics and researchers | Universities, research institutes | Scientific contributors and collaborators | Relevant for data, publications, research partnerships, and training |
| Life sciences innovators | Biotech, medtech, diagnostics | Product and access strategy | Need evidence planning, value communication, and market access support |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Vienna host city | Local healthcare, academic, and policy participants | Medium | Convenient for Austrian stakeholders and regional institutions |
| Austria / Central Europe | National health systems, universities, pharma affiliates, consultancies | High | Strong regional attendance expected due to the Vienna location |
| Western Europe | Payers, HTA bodies, pharma, CROs, providers | High | Large concentration of access, reimbursement, and evidence stakeholders |
| Rest of Europe | Broader European payer-policy and life sciences community | High | ISPOR Europe is a pan-European scientific conference with broad cross-border participation |
| North America | Global pharma, HEOR, consulting, and academic attendees | Medium | Likely participation from multinational life sciences and research organizations |
| Global / international | Global healthcare ecosystem, especially evidence and access stakeholders | High | Official event page states attendees from 100+ countries |
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The official event page states participation from more than 100 countries, making the conference globally relevant for HEOR and market access stakeholders. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| National Institute for Health and Care Excellence (NICE) | Government / HTA organization | Core payer and evidence appraisal stakeholder for HEOR and value assessment | nice.org.uk | Policy Lead, Evidence Review Manager, HTA Scientist | Strong Market Fit, Attendance Not Confirmed |
| European Medicines Agency (EMA) | Regulatory agency | Influential in evidence standards, scientific advice, and access discussions | ema.europa.eu | Scientific Officer, Policy Officer, Regulatory Affairs Lead | Strong Market Fit, Attendance Not Confirmed |
| IQVIA | Healthcare analytics / services | Common HEOR, RWE, and market access services provider | iqvia.com | VP HEOR, RWE Director, Market Access Director | Strong Market Fit, Attendance Not Confirmed |
| Amgen | Biopharma manufacturer | Needs evidence generation and access strategy for therapies across markets | amgen.com | Director Market Access, HEOR Lead, Value Evidence Manager | Strong Market Fit, Attendance Not Confirmed |
| Roche | Biopharma / diagnostics | High HEOR, payer evidence, and access relevance | roche.com | Head of HEOR, Market Access Director, Evidence Generation Lead | Strong Market Fit, Attendance Not Confirmed |
| Novartis | Biopharma manufacturer | Large access, reimbursement, and evidence generation organization | novartis.com | Global HEOR Director, Payer Strategy Lead, Market Access VP | Strong Market Fit, Attendance Not Confirmed |
| Pfizer | Biopharma manufacturer | Strategic payer and outcomes research stakeholder | pfizer.com | Director Market Access, HEOR Manager, Value & Access Lead | Strong Market Fit, Attendance Not Confirmed |
| AstraZeneca | Biopharma manufacturer | Key market access and evidence stakeholder across therapeutic areas | astrazeneca.com | HEOR Director, Payer Evidence Lead, Access Strategy Manager | Strong Market Fit, Attendance Not Confirmed |
| Sanofi | Biopharma manufacturer | Value evidence and payer engagement are central to commercialization | sanofi.com | Access Lead, Outcomes Research Director, Evidence Strategy Director | Strong Market Fit, Attendance Not Confirmed |
| Bristol Myers Squibb | Biopharma manufacturer | Needs evidence, reimbursement, and policy engagement support | bms.com | Market Access Director, HEOR Lead, Value Evidence Manager | Strong Market Fit, Attendance Not Confirmed |
| Merck KGaA / MSD affiliates | Biopharma manufacturer | Active in payer evidence and access discussions in Europe | merckgroup.com / msd.com | HEOR Manager, Global Market Access, RWE Director | Strong Market Fit, Attendance Not Confirmed |
| European Commission / health policy stakeholders | Government / public sector | Influence on healthcare policy, access, and regulation | ec.europa.eu | Policy Officer, Health Program Manager, Regulatory Affairs Lead | Strong Market Fit, Attendance Not Confirmed |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Market Access Officer / VP Market Access | Commercial / Access | Executive | Owns access strategy, evidence needs, and vendor selection |
| 1 | Director / Head of HEOR | HEOR / Evidence Generation | Director / Senior Director | Primary buyer for outcomes research, modeling, and evidence services |
| 1 | RWE / Epidemiology Lead | Medical Affairs / HEOR | Manager to Director | Evaluates data, registries, observational studies, and analytics vendors |
| 2 | Payer Strategy / Value & Access Lead | Access / Commercial | Manager to Director | Needs payer insight, value communication, and reimbursement tools |
| 2 | Health Economist / Outcomes Research Scientist | HEOR / Research | Individual Contributor / Manager | Technical evaluator of methods, models, and evidence generation services |
| 2 | HTA / Pricing & Reimbursement Manager | Market Access / Policy | Manager to Director | Directly aligned with payer submissions and reimbursement strategy |
| 2 | Medical Director / Medical Affairs Lead | Medical Affairs | Director / Senior Director | Influences scientific strategy and evidence generation priorities |
| 3 | Policy Analyst / Health Policy Lead | Public Affairs / Government | Analyst to Director | Monitors regulatory and reimbursement trends, important for policy solutions |
| 3 | Professor / Principal Investigator | Academia / Research | Senior | Drives scientific output, collaborations, and methodological innovation |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Pharmaceuticals | Primary sponsor/attendee ecosystem for HEOR and market access | Market access, evidence generation, payer strategy |
| 1 | Biotechnology | Innovative therapy developers need evidence and reimbursement support | HEOR consulting, RWE, value communication |
| 1 | Hospital & Health Care | Provider-side decision-makers are relevant to outcomes and access | Health system evidence, quality improvement, outcomes tools |
| 1 | Government Administration | HTA, reimbursement, and policy stakeholders are central to the event | Policy, evidence review, public-sector engagement |
| 1 | Information Services | Data, evidence, and insights products are highly relevant | RWE databases, analytics, evidence platforms |
| 2 | Market Research | Supports payer and provider insights for commercialization | Insights studies, advisory panels, landscape intelligence |
| 2 | Management Consulting | Frequent buyers and advisors in access and HEOR projects | Strategic advisory, payer strategy, evidence planning |
| 2 | Research | Academic and applied research are core to the conference | Research collaboration, publication support, study design |
| 2 | Information Technology & Services | Data platforms and analytics systems support HEOR workflows | Data integration, AI analytics, workflow software |
| 3 | Medical Devices | Access and outcomes evidence also matters to medtech companies | Value dossiers, health economics, payer studies |
| 3 | Biotechnology / Medical Devices consultancies and CRO-adjacent services | Common service buyers for evidence and access support | Outsourced analytics, model building, literature reviews |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 6,000+ | Confirmed by organizer | Official event page | Organizer-published figure on the current event page |
| Exhibitor count | Attendance figure not publicly confirmed by the organizer | Not publicly confirmed | Official site provides exhibitor directory but no verified count in the supplied text | Use exhibitor directory for list-building once current-year entries are verified |
| Buyer count | Attendance figure not publicly confirmed by the organizer | Not publicly confirmed | No buyer-only count published in provided text | Buyer mix likely spans payers, pharma, providers, and policymakers |
| Speaker count | 140+ sessions | Confirmed by organizer | Official event page | Speaker headcount not stated in provided text |
| Sponsor count | Attendance figure not publicly confirmed by the organizer | Not publicly confirmed | No sponsor count in the supplied text | Consult current sponsorship page for verified names and tiers |
| Historical attendance | Prior-year attendance evidence available on official ISPOR event pages | Historical / prior-year evidence | ISPOR official conferences archive / past event pages | Useful for trend analysis, not a substitute for 2026 final registration data |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| HEOR | Cost-effectiveness and outcomes evidence | Meet teams seeking modeling, evidence synthesis, and submission support | HEOR consulting, economic modeling, literature review services |
| Real-world evidence | Observational data and longitudinal insights | Target buyers needing registries, claims analytics, and evidence platforms | RWE data services, analytics software, data partnerships |
| Health technology assessment | Submission-quality evidence and appraisal readiness | Engage HTA-facing teams and payer organizations | HTA dossiers, value communication, evidence strategy |
| Payer engagement | Understand payer requirements and access barriers | Opportunity to sell market access intelligence and advisory services | Payer research, access strategy, stakeholder mapping |
| Policy and regulation | Track changing reimbursement and policy frameworks | Engage public-sector and regulatory audiences | Policy briefs, advisory support, regulatory intelligence |
| Scientific dissemination | Publish and share research methods and findings | Useful for content marketing and thought leadership outreach | Publishing support, scientific communications, congress strategy |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The event attracts payers, pharma, HTA, policymakers, and research buyers directly tied to evidence and access. |
| Decision-maker availability | High | Strong presence of director-level and above stakeholders in HEOR, access, policy, and payer functions. |
| Data collection potential | High | Conference audience and exhibitor ecosystem support list-building, though current-year confirmed participant data may require verification. |
| Apollo targeting potential | Very High | Clear match to pharmaceutical, biotech, hospital, government, and consulting buyer segments with identifiable job titles. |
| Geographic targeting potential | High | Strong for Europe with global reach from the official 100+ country claim. |
| Best outreach approach | Account-based + role-based | Target HEOR, market access, policy, and RWE teams with content on access, evidence, and reimbursement. |
| Overall lead quality | Very High | One of the strongest healthcare conferences for qualified B2B lead generation in evidence, access, and policy. |
| Best use case | Attendee list building and targeted outreach | Best for vendor prospecting, meeting booking, sponsor activation, and high-value account targeting. |
| Limitations / risks | Medium | Current-year exhibitor and attendee lists are not fully confirmed in the supplied text, so verified prospecting requires checking the live directory. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Pharmaceuticals; Biotechnology; Hospital & Health Care; Government Administration; Information Services; Management Consulting; Research; Medical Devices; Information Technology & Services; Market Research | Focus on organizations most likely to buy HEOR, access, data, and evidence services |
| Departments | Market Access; HEOR; Medical Affairs; RWE; Commercial; Policy; Government Affairs; Research; Analytics | Align with conference content and buying authority |
| Seniority | Manager; Director; Senior Director; VP; CXO; Head of | Prioritize decision-makers and budget holders |
| Job titles | Head of HEOR, Market Access Director, RWE Lead, HTA Manager, Payer Strategy Director, Value Evidence Lead, Health Economist, Policy Lead | Identify the best-fit functional buyers for outreach |
| Geography | Austria; Germany; Switzerland; UK; France; Benelux; Nordics; Central and Eastern Europe; EU-wide; North America | Match the event’s European center of gravity while preserving global reach |
| Employee size | 200-500; 501-1,000; 1,001-5,000; 5,001-10,000; 10,000+ | Capture both mid-market specialists and enterprise life sciences buyers |
| Keywords | HEOR, health economics, outcomes research, real-world evidence, HTA, market access, payer, reimbursement, value evidence, patient access | Improve search precision for event-aligned roles |
| Company type | Public company; enterprise; government; nonprofit; association; research institution | Prioritize organizations most likely to participate in HEOR and policy discussions |
Suggested Apollo Search Logic: ("health economics" OR HEOR OR "real world evidence" OR RWE OR "market access" OR HTA OR reimbursement OR payer OR "value evidence") AND (Director OR VP OR Head OR Manager)
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| ISPOR Europe 2026 official event page | Official organizer source | Event name, dates, city, country, attendee reach, sessions, and thematic positioning | Very High |
| ISPOR home page | Official society website | Organization identity, HEOR focus, and society context | Very High |
| Official event navigation and content blocks | Official site content | Exhibits & sponsorship presence, exhibitor directory existence, venue information section, and conference structure | High |
| Provided official website excerpt | Primary source text supplied by user | Verified attendee estimate, international reach, and conference positioning | Very High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to ISPOR Europe - The Professional Society for Health Economics and Outcomes Research — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.